Abstract
Cancer is a common disease in Western society that can affect any organ system. It has a high morbidity and mortality despite advances in treatment over the last hundred years. There is a clear need for new approaches to cancer chemotherapy including the possibility of reducing systemic adverse effects associated with current treatments. Vesicle trafficking is an essential cellular process that is perhaps not fully recognized. There is mounting evidence that vesicle trafficking, including the release of extracellular microvesicles, is a highly important process in tumourigenesis. Diverse aspects of tumourigenesis including invasion, metastasis, cell cycle regulation, angiogenesis, tumour immune privilege, neoplastic coagulopathy and multidrug resistance can be explained by altered vesicle trafficking in cancer cells. This paper reviews the evidence in the scientific and patent literature for the role of vesicle trafficking in tumourigenesis and suggests a number of targets and strategies that may be important for cancer therapeutics.
Keywords: Vesicle trafficking, cancer, chemotherapy, multidrug resistance, vesicle, exosome, microvesicle, microparticle, membrane vesicle, exocytosis
Recent Patents on Anti-Cancer Drug Discovery
Title: Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Volume: 3 Issue: 2
Author(s): Paul K. Wright
Affiliation:
Keywords: Vesicle trafficking, cancer, chemotherapy, multidrug resistance, vesicle, exosome, microvesicle, microparticle, membrane vesicle, exocytosis
Abstract: Cancer is a common disease in Western society that can affect any organ system. It has a high morbidity and mortality despite advances in treatment over the last hundred years. There is a clear need for new approaches to cancer chemotherapy including the possibility of reducing systemic adverse effects associated with current treatments. Vesicle trafficking is an essential cellular process that is perhaps not fully recognized. There is mounting evidence that vesicle trafficking, including the release of extracellular microvesicles, is a highly important process in tumourigenesis. Diverse aspects of tumourigenesis including invasion, metastasis, cell cycle regulation, angiogenesis, tumour immune privilege, neoplastic coagulopathy and multidrug resistance can be explained by altered vesicle trafficking in cancer cells. This paper reviews the evidence in the scientific and patent literature for the role of vesicle trafficking in tumourigenesis and suggests a number of targets and strategies that may be important for cancer therapeutics.
Export Options
About this article
Cite this article as:
Wright K. Paul, Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489208784638730
DOI https://dx.doi.org/10.2174/157489208784638730 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Majra Honey Abrogated the Normal and Cancer Cells Proliferation Inhibition by Juniperus procera Extract and Extract/Honey Generated AgNPs
Anti-Cancer Agents in Medicinal Chemistry Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts
Anti-Cancer Agents in Medicinal Chemistry Tetraplex Binding Molecules as Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology Evolutioninthe Pharmacogenetics and Pharmacogenomics of Inflammatory Bowel Disease - Order Slowly Rises from the Chaos
Current Pharmacogenomics Tumour Targeting with Systemically Administered Bacteria
Current Gene Therapy The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets Anti-cancer Research on Arnebiae radix-derived Naphthoquinone in Recent Five Years
Recent Patents on Anti-Cancer Drug Discovery Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the VHL Mutation p.P81S (c.241C>T)
Current Genomics Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Role of α6β4 Integrin in Cell Motility, Invasion and Metastasis of Mammary Tumors
Current Protein & Peptide Science Purinergic (P2) Receptor Control of Lower Genitourinary Tract Function and New Avenues for Drug Action: An Overview
Current Pharmaceutical Design A Pan-Cancer Review of <i>ALK</i> Mutations: Implications for Carcinogenesis and Therapy
Current Cancer Drug Targets Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science Modulation of P2 Receptors on Pancreatic β-cells by Agonists and Antagonists: A Molecular Target for Type 2 Diabetes Treatment
Current Diabetes Reviews Smart Biodecorated Hybrid Nanoparticles
Current Bionanotechnology (Discontinued) The Apoptosis Mechanism of Epirubicin Combined with BCG on Human Bladder Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting Multiplicity: The Key Factor for Anti-Cancer Nanoparticles
Current Medicinal Chemistry